Tylenol & autism: Trump’s warning sparks firestorm — what pregnant women really need to know

In the United States, a heated debate is unfolding. At its core: acetaminophen, the active ingredient in Tylenol.

Scientists are asking if its use during pregnancy raises the risk of autism spectrum disorder (ASD) or attention deficit hyperactivity disorder (ADHD) in children.

A 2021 consensus statement published in Nature Reviews Endocrinology following a study led by Ann Z. Bauer (Department of Public Health, University of Massachusetts School of Health Sciences, Lowell) urged caution, citing multiple studies linking prenatal acetaminophen exposure to higher rates of ASD and ADHD symptoms.

However, the US Food and Drug Administration (FDA) says evidence remains inconclusive and advises continued, careful use when medically necessary.

Does acetaminophen (the active ingredient in Tylenol) taken by pregnant women really raise the risk of autism and ADHD in their children?

The question has become a politically-charged hot potato in America.

It has been amplified by recent federal announcements under the Trump administration, despite scientific consensus that no causal link has been established.

Autism diagnoses have risen sharply — now affecting about 1 in 31 US children, up nearly 400% since 2000.

Experts attribute this largely to improved screening, broader diagnostic criteria, and greater awareness, not a single environmental trigger like Tylenol.

At its core, the controversy pits observational studies showing a statistical association (but not causation) between prenatal (taken during pregnancy) acetaminophen exposure and higher autism/ADHD rates against larger, more rigorous studies finding no such link.

Proponents of the risk (including some researchers and administration officials) argue that acetaminophen may disrupt foetal brain development through mechanisms like oxidative stress or hormonal interference, especially with prolonged use.

Critics, including major medical groups, emphasise that associations could stem from confounding factors — e.g., the fevers or pains prompting Tylenol use might themselves harm foetal development.

Underlying genetics could also play a role.

The debate escalated into a national flashpoint when President Trump, flanked by HHS Secretary Robert F. Kennedy Jr. — a longtime vaccine skeptic who has promoted environmental autism theories — held a White House press conference blaming Tylenol for much of the "autism epidemic."

Trump repeatedly urged pregnant women, "Don't take Tylenol," and claimed communities without access to it have "no autism."

The FDA simultaneously announced plans for a label change on acetaminophen products to warn of a "possible association" with autism and ADHD, based on cohort studies like the Nurses’ Health Study II and Boston Birth Cohort.

However, the FDA's own statement clarified: "A causal relationship has not been established, and there are contrary studies."

Medical organisations like the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Foetal Medicine (SMFM) pushed back, calling the move "misleading" and "risky", as untreated pain or fever during pregnancy can lead to the following:

Tylenol's manufacturer, Kenvue, also disputed the claims, stating "over a decade of rigorous research" shows no causal link.

Johns Hopkins (2019): Cord blood analysis of ~1,000 children; highest acetaminophen levels linked to ~3x higher ADHD/autism risk.

Harvard/Mount Sinai Review (2025): Analysed 46 studies; higher-quality ones more likely to show links to autism/ADHD, suggesting prenatal exposure raises risk via epigenetic changes.

Nurses’ Health Study II: Long-term data showing chronic use tied to elevated risks.

#1. Swedish Cohort (2024, JAMA): 2.4 million children; no increased risk for autism/ADHD even in sibling comparisons (controlling for genetics). Absolute risk: 1.33% (unexposed) vs. 1.53% (exposed).

#2. Autism Speaks Review (2024): Initial associations vanished in sibling analyses; likely due to underlying factors like maternal illness.

#3. Overall Meta-Analyses: No dose-response pattern; risks don't increase with more exposure in controlled designs.

The brouhaha also ties into broader autism causation debates, with Kennedy's report speculating on factors like vitamin deficiencies (e.g., folate, treatable with leucovorin) alongside Tylenol — claims experts call "unproven" and "oversimplified," as autism is multifactorial (genetics ~80-90%, per experts).

The debate didn't start in 2025 — roots trace to the 2010s — but the current firestorm was ignited by:

Acetaminophen remains the only over-the-counter pain/fever reliever recommended as safe during pregnancy by ACOG, CDC, and FDA —alternatives like ibuprofen (NSAIDs) risk miscarriage or foetal heart/kidney issues after 20 weeks.

Experts say Untreated fever raises autism risk by ~30% via infection/inflammation, and chronic pain can lead to maternal stress or hypertension.

No study proves causation with autism, and large trials show minimal absolute risk (e.g., <0.2% increase).

Key guidance:

The Tylenol brouhaha reflects a clash of preliminary science, politics, and public health caution — fuelled by Trump's blunt rhetoric and Kennedy's advocacy — but it's not settled science.

Pregnant women should prioritise evidence-based advice from providers over politically-charged pronouncements.